Lantheus initiated with an Outperform at JMP Securities

JMP Securities initiated coverage of Lantheus with an Outperform rating and $120 price target. The company has long been a leader in the field of radiopharmaceuticals, which are very important for both diagnostic imaging and therapeutic delivery, the analyst tells investors in a research note. Following acquisitions, the firm says the company has transformed "into a disruptive pioneer and a growth juggernaut." Lantheus’ financial profile is "largely unparalleled," with sales essentially doubling and earnings more than tripling over the last three years, contends JMP. It thinks the stock "still looks very cheap versus similar-sized, high-growth peers."